

1 A Phase 3, Randomized, Controlled Trial of Astodrimmer 1% Gel for Preventing
2 Recurrent Bacterial Vaginosis

3 Jane R. SCHWEBKE, MD¹, Belvia A. CARTER, MD², Arthur S. WALDBAUM, MD³, Ms.

4 Kathy J. AGNEW, BS⁴, Jeremy R.A. PAULL, PhD⁵, Ms. Clare F. PRICE, BPharm⁵, Mr. Alex

5 CASTELLARNAU, VMD⁵, Philip MCCLOUD, PhD⁶, George R. KINGHORN, MD, FRCP⁷

6 ¹ Division of Infectious Diseases, University of Alabama at Birmingham, Birmingham, AL, USA

7 ² Women's Physician Group, Memphis, TN, US

8 ³ Downtown Women's Health Care, Denver, CO, US

9 ⁴ Department of Obstetrics and Gynecology, University of Washington, Seattle, WA, US

10 ⁵ Starpharma Pty Ltd, Melbourne, VIC, Australia

11 ⁶ McCloud Consulting Group, Sydney, NSW, Australia

12 ⁷ Royal Hallamshire and Sheffield Teaching Hospitals, Sheffield, United Kingdom

13 **Conflict of Interest Statement:** JRS is a paid consultant for Starpharma Pty Ltd, Talis One,

14 Toltec, Lupin Pharmaceuticals, and Hologic. ASW received research funding from Gage

15 Development Company.

16 **Financial Disclosure Statement:** This study was funded by Starpharma Pty Ltd. Starpharma Pty

17 Ltd was responsible for the study design, the collection, analysis and interpretation of data, the

18 decision to submit the article for publication, and preparation of the manuscript. The funder

19 provided support in the form of research funding for this study to JRS, BAC and ASW. The

20 funder provided support in the form of salaries for JRAP, CFP and AC, and consulting fees for
21 KJA, PMcC and GRK.

22 **Clinical Trial Registration:** Date of Registration: September 12, 2014; First Patient Enrolled:
23 October 13, 2014; Identification No.: NCT02237950; clinicaltrials.gov

24 **Paper Presentation:** The 46th Annual Meeting of The Infectious Diseases Society for Obstetrics
25 and Gynecology (IDSOG), Big Sky, Montana, USA, August 8-10, 2019

26 **Author for Correspondence:**

27 Jeremy R.A. Paull, PhD

28 4-6 Southampton Crescent, Abbotsford, Victoria 3067, Australia

29 Telephone (Work): +61 3 8532 2736

30 Email: jeremy.paull@starpharma.com

31 **Word Count:** Abstract=496; Main text=2993

32

33 **Condensation**

34 This Phase 3 randomized controlled trial demonstrated efficacy and safety of Astodrimmer 1% Gel
35 for the prevention of recurrent bacterial vaginosis.

36 **Short Title**

37 Astodrimmer Gel for prevention of bacterial vaginosis.

38 **AJOG at a Glance**

39 A. Why was the study conducted?

40 The study was conducted to confirm the efficacy and safety of Astodrimmer 1% Gel, which has a
41 novel, non-antibiotic mechanism of action related to disruption of biofilms, for the prevention of
42 recurrent bacterial vaginosis.

43 B. What are the key findings?

44 Astodrimmer 1% Gel administered every second day for 16 weeks, was effective and superior to
45 placebo for the prevention of recurrent bacterial vaginosis in women with a history of recurrent
46 BV, and was well-tolerated.

47 C. What does this study add to what is already known?

48 These results support the use of Astodrimmer 1% Gel, which was previously shown to be effective
49 for the treatment of women with bacterial vaginosis, as a safe and effective product for the
50 prevention of recurrent bacterial vaginosis.

51

52 **Abstract**

53 **Background:** Bacterial vaginosis is highly recurrent after antibiotic treatment, and prevention
54 represents an unmet medical need. Astodrimmer 1% Gel contains a novel dendrimer that blocks
55 bacterial attachment and has been shown to effectively treat bacterial vaginosis.

56 **Objective:** The objective of the study was to confirm the efficacy and safety of Astodrimmer 1%
57 Gel to prevent recurrence of bacterial vaginosis.

58 **Study Design:** 864 women with a current episode of bacterial vaginosis and a history of
59 recurrent bacterial vaginosis were enrolled in the open-label phase of the study to receive oral
60 metronidazole (500 mg twice daily for 7 days) at 77 centers in North America. 586 women
61 successfully treated with metronidazole were randomly assigned 1:1 to Astodrimmer 1% Gel or
62 placebo at a dose of 5 g vaginally every second day for 16 weeks, and followed for a further 12
63 weeks off-treatment. The primary endpoint was recurrence of bacterial vaginosis (presence of
64 ≥ 3 Amsel criteria) at or by Week 16. Secondary endpoints of recurrence of bacterial vaginosis at
65 or by Week 16 included time to recurrence, subject-reported symptoms of bacterial vaginosis,
66 individual Amsel criteria, Nugent score 7-10, and the composite of Amsel criteria and Nugent
67 score. Adverse events were monitored throughout the study.

68 **Results:** Astodrimmer 1% Gel was superior to placebo for the primary and many secondary
69 efficacy measures. At or by Week 16, bacterial vaginosis recurred in 44.2% (130/294) of women
70 receiving astodrimmer and 54.3% (158/291) receiving placebo ($P = .015$). Time to recurrence of
71 bacterial vaginosis was significantly longer for women receiving astodrimmer compared with
72 placebo (Kaplan-Meier survival curves, $P = .007$). Recurrence of subject-reported symptoms at
73 or by Week 16 was also significantly lower in the astodrimmer arm compared with placebo

74 (vaginal odor and/or discharge, 27.9% [75/269] vs 40.6% [108/266], $P = .002$). A significantly
75 lower proportion of patients receiving astodrimmer compared with placebo had recurrence of
76 bacterial vaginosis at or by Week 16 by other secondary measures, including individual Amsel
77 criteria (vaginal discharge and clue cells), Nugent score 7-10, and composite of Nugent score and
78 Amsel criteria. Recurrence of subject-reported bacterial vaginosis symptoms, vaginal odor and/or
79 discharge, was significantly lower in the astodrimmer arm compared with placebo up to 8 weeks
80 after cessation of therapy (36.1% [97/269] vs 45.5% [121/266], $P = .027$). During the 12-week
81 follow-up, recurrence of ≥ 3 Amsel criteria after cessation of therapy in women given astodrimmer
82 was lower than in those given placebo, but the differences were not statistically significant.

83 Adverse events were infrequent, and rates were similar between placebo and astodrimmer groups,
84 except for vulvovaginal candidiasis and urinary tract infection, which occurred more often in
85 women receiving astodrimmer.

86 **Conclusions:** Astodrimmer 1% Gel, administered every second day for 16 weeks, was effective
87 and superior to placebo for prevention of recurrent bacterial vaginosis in women with a history
88 of recurrent BV, and was well-tolerated. These results support a role for Astodrimmer 1% Gel as
89 an effective long-term treatment to prevent recurrent bacterial vaginosis that avoids potential
90 issues associated with conventional antibiotics.

91

92 **Keywords**

93 Astodrimmer Gel; bacterial vaginosis; biofilm; prevention; recurrent bacterial vaginosis; SPL7013;
94 VivaGel

95

96 **Introduction**

97 Bacterial vaginosis (BV) is the most common vaginal infection and approximately twice as
98 common as vulvovaginal candidiasis.¹ BV recurrence rates are high at 43% to 52% within 3 to 6
99 months of treatment.² BV is a risk factor for serious medical sequelae, including pre-term birth,
100 and acquisition and transmission of human immunodeficiency virus (HIV) and other sexually
101 transmitted infections.^{3,4} Recurrent BV has particularly significant psychosocial impacts on
102 women, including severely affecting self-esteem and sex life, and carries a high economic
103 burden.^{5,6}

104 In the US, there are no approved therapies and there have been no other large, adequately
105 powered, well-controlled studies of interventions for prevention of recurrent BV. Antibiotic
106 therapies are used prophylactically off-label over extended periods for reducing recurrence of
107 BV, but are associated with increased risk of side effects⁷ and potential for antibiotic resistance
108 development.⁸ It is not realistic to expect a one-time therapy to provide long-term cure of BV,
109 given the lifestyle factors associated with recurrence.⁹ Therefore, therapies for preventing BV
110 recurrence that are suitable for longer-term use are urgently required.^{10,11}

111 Astodrimmer sodium (VivaGel, Starpharma Pty Ltd, Melbourne, Victoria, Australia) is a highly
112 branched, polyanionic dendrimer that blocks attachment of bacteria to cells, preventing
113 formation of bacterial biofilms, which are central to the pathogenesis of BV and not targeted by
114 existing therapies.^{12,13,14,15,16} Astodrimmer Gel was effective for treatment of women with BV,
115 achieving clinical cure at the end of a 7-day treatment course, and was well-tolerated and not
116 systemically absorbed.^{17,18}

117 Astodrimer Gel offers potential as a non-antibiotic approach suitable for longer-term
118 administration to prevent recurrent BV. This adequately powered, placebo-controlled, phase 3
119 study assessed the efficacy and safety of Astodrimer 1% Gel for preventing recurrent BV.

120 **Materials and Methods**

121 **Study Design**

122 This was a Phase 3, double-blind, multicenter, randomized, placebo-controlled study assessing
123 the efficacy and safety of Astodrimer 1% Gel applied vaginally for 16 weeks compared with
124 placebo (hydroxyethyl cellulose placebo gel) to prevent recurrence of BV.

125 The study complied with the Declaration of Helsinki, was conducted in accordance with Good
126 Clinical Practice, regulatory guidelines, and relevant local legislation, and was approved by an
127 institutional review board on June 20, 2014 (Quorum Review, Inc.). Patient enrolment
128 commenced October 2014 with last follow-up in February 2017.

129 All patients provided written informed consent and were screened for eligibility at the Screening
130 visit. Eligible patients with a current symptomatic episode of BV and a history of recurrent BV
131 were enrolled in an open-label treatment phase and received oral metronidazole (500mg), twice
132 daily for 7 days. At the second study visit (Baseline), 3 to 5 days after completion of
133 metronidazole, women with resolution of BV were randomized in a 1:1 ratio to either
134 Astodrimer 1% Gel or placebo using a computer-generated randomization list based upon a
135 permutation block procedure.

136 The active gel and placebo were colorless, clear gels packaged in identical pre-filled, vaginal
137 applicators. Each applicator contained a single dose (5 g) and was individually overwrapped in a

138 sealed pouch. Seventeen overwrapped applicators (14 doses and 3 spare) were packed in a
139 tamper-evident carton labelled with a unique study medication number, which was allocated
140 along with a unique patient identification number using an interactive randomization system.
141 One carton, sufficient for 4 weeks' dosing, was dispensed to each woman at Baseline, and at
142 Week 4, 8 and 12 study visits. Women self-administered a dose vaginally, every second day for
143 16 consecutive weeks (56 doses total) and attended visits for assessment of BV and adverse
144 events (AEs) every 4 weeks during, and for 12 weeks after end of, treatment. Both care providers
145 and patients were unaware of treatment allocations. Women could withdraw from the study at
146 any time.

147 Women who had a recurrence of BV prior to Week 16 stopped treatment, ended the study and
148 were offered BV therapy in line with local practice. A woman was considered to have completed
149 the study if she reached the final follow-up visit (Week 28) recurrence free or had confirmed BV
150 recurrence at any time.

151 **Study Population**

152 Women aged 18-45 years with a current diagnosis of BV, defined as presence of ≥ 3 Amsel
153 criteria (discharge; vaginal fluid pH ≥ 4.5 ; $\geq 20\%$ clue cells; and/or positive 10% potassium
154 hydroxide whiff test),¹⁹ Nugent score (NS) of 4-10²⁰ and self-report of characteristic BV
155 symptoms (abnormal vaginal odor and/or discharge), and a history of recurrent BV defined as at
156 least 2 documented episodes of BV in the past year, were enrolled in the open-label phase.

157 Women who were pregnant, planning to become pregnant, lactating, or within 3 months of last
158 pregnancy outcome at enrollment, women testing positive for urinary tract infection (UTI),
159 *Chlamydia trachomatis*, *Neisseria gonorrhoea* or *Trichomoniasis vaginalis* infections, or positive

160 for and/or having signs/symptoms of active genital herpes simplex virus (HSV)-1 or HSV-2 at
161 Screening, were excluded. Women who had received antifungal or antimicrobial therapy
162 (systemic or vaginal) within 14 days of enrolment were also excluded.

163 Women who were asymptomatic and were negative for Amsel criteria for discharge, whiff test
164 and clue cells following the open-label phase, were randomized for the double-blind treatment
165 phase.

166 Concomitant systemic and vaginal antimicrobial therapies, vaginal antifungals, or any other kind
167 of vaginal products were not permitted during the study.

168 **Outcomes**

169 The primary efficacy endpoint was recurrence of BV at or by Week 16, defined as the presence
170 of ≥ 3 Amsel criteria. Secondary efficacy endpoints included presence of subject-reported BV
171 symptoms, recurrence of individual Amsel criteria, BV recurrence determined by NS 7-10, and
172 BV recurrence determined as the presence of ≥ 3 Amsel criteria and a NS ≥ 4 , at or by Week 16.
173 Time to BV recurrence and BV recurrence at any of the follow-up visits were also secondary
174 efficacy endpoints.

175 Questionnaires (SF-36v2 [Short-form-36-item Health Survey version 2], Global Health Outcome,
176 BISF-W [Brief Index of Sexual Functioning for Women] and CSFQ-F [Changes in Sexual
177 Functioning Questionnaire – Female version]), were used to determine impact of product on
178 quality of life (QoL) by capturing mean change of response scores at or by Week 16 compared to
179 screening and/or baseline.

180 AEs were monitored throughout the study.

181 **Statistical Analyses**

182 Primary and secondary efficacy analyses using logistic regression, with missing BV recurrence
183 data at Week 16 imputed as recurrence and treatment as the only factor in the model, were
184 performed on the modified intent-to-treat (mITT) population, which comprised all women
185 randomized who administered ≥ 1 dose of study product. This population was also used to
186 determine safety endpoints.

187 The primary efficacy endpoint was also analyzed for population subgroups based on Nugent
188 category at screening and baseline, method of contraception, race, sexual activity during the
189 study, change in sexual partner, use of a vaginal product, number of previous BV episodes, body
190 mass index (BMI) and socio-economic status.

191 Categorical variables were summarized using frequency counts and percentages of patients in
192 each category. Descriptive statistics were calculated for each continuous variable.

193 Survival curves for time to recurrence were estimated using Kaplan-Meier methodology. A log-
194 rank test was used to test the difference between survival curves of the treatment arms. Hazard of
195 BV recurrence was analyzed within the framework of the Kaplan-Meier survival analysis.

196 Statistical analyses were performed using SAS (Version 9.2; SAS Institute, Cary, NC).

197 **Sample Size Calculation**

198 Assuming BV recurrence rates of 32% and 45% for Astodrimer Gel and placebo, respectively, a
199 sample size of 308 evaluable participants per treatment arm provided 90% power with a 2-sided
200 test to detect a treatment difference with alpha significance level of 0.05. Therefore, 310 per

201 treatment arm and 620 participants overall were to be randomized into the double-blind
202 treatment phase of the study.

203 **Results**

204 **Disposition and Demographics**

205 A total of 864 women were enrolled in the open-label phase of the study to receive
206 metronidazole; 586/864 (67.8%) eligible women entered the double-blind treatment phase and
207 were randomized to either Astodrimmer 1% Gel (N=295) or placebo (N=291) at 67 sites in the US,
208 4 in Canada, 4 in Mexico and 2 in Puerto Rico. The mITT population included 585 women.
209 Treatment groups were well-balanced with respect to demographic and baseline characteristics
210 (Table 1). The majority of women completed the study and were included in the mITT
211 population (Figure 1).

212 **Efficacy**

213 Astodrimmer 1% Gel was superior to placebo for the primary endpoint, with 44.2% (130/294)
214 given astodrimmer compared to 54.3% (158/291) given placebo experiencing recurrence of BV at
215 or by Week 16; $P = .015$) (Table 2). The recurrence of subject-reported symptoms of BV at or by
216 Week 16 was also significantly lower in the astodrimmer arm compared with placebo (Table 2).
217 Kaplan-Meier survival curves for time to recurrence separated after Week 4 and remained so at
218 Week 16; $P = .007$ (Figure 2).

219 Recurrence of individual Amsel criteria at or by Week 16 was lower in the astodrimmer group than
220 in the placebo group, with exception of vaginal fluid pH (Table 2). In addition, a lower

221 proportion of patients receiving astodrimmer compared with placebo had BV recurrence at or by
222 Week 16 based on NS 7-10, and the composite of ≥ 3 Amsel criteria and NS ≥ 4 (Table 2).

223 During the 12-week follow-up phase, recurrence of BV (≥ 3 Amsel criteria) in women given
224 astodrimmer was lower than in those given placebo but the differences were not statistically
225 significant (Table 3).

226 Recurrence of patient-reported BV symptoms of vaginal odor and/or discharge was statistically
227 significantly lower in the astodrimmer arm compared with placebo up to 8 weeks after cessation of
228 therapy (Table 3).

229 QoL scores were similar between treatment groups at screening and baseline. Total CSFQ-F
230 scores at or by Week 16 increased slightly in the astodrimmer group and were slightly decreased in
231 the placebo group, with a mean change from baseline of +1.0 (95% CI: -0.4, 2.3) and -0.8 (95%
232 CI: -3.0, 1.3), respectively, suggesting a slightly improved sexual function in the astodrimmer
233 group. The change in BISO-W *composite score* was in line with the CSFQ-F findings and
234 changed by +1.6 (95% CI: -0.5, 3.7) in the astodrimmer group but only by +0.1 (95% CI: -2.0, 2.1)
235 in the placebo group. There were no remarkable differences between groups in terms of mean
236 score change for the SF-36v2 and Global Health Outcome questionnaires.

237 Subgroup recurrence rates were in line with those for the mITT analyses. The Breslow-Day test
238 for homogeneity of odds ratios of astodrimmer versus placebo was non-significant for each
239 subgroup factor ($P > .150$, except Age, $P = .098$); data not shown. Lower recurrence rates at or
240 by Week 16 for women randomized to astodrimmer compared to placebo were statistically
241 significant for several subgroup categories, including women with screening NS of 7-10 (46.2%
242 [108/234] vs 57.7% [128/222], $P = .014$), black women (53.7% [79/147] vs 68.1% [96/141],

243 $P = .013$), women who had penile-vaginal sexual acts during the treatment period (38.9%
244 [96/247] vs 50.6% [121/239], $P = .009$), and women who used condoms during treatment period
245 (33.0% [29/88] vs 49.4% [44/89], $P = .027$).

246 **Safety/tolerability**

247 The overall incidence of AEs was 54.1% (159/294) for Astodrimmer Gel and 47.4% (138/291) for
248 placebo (Table 4). AEs potentially treatment-related occurred in 12.6% (37/294) of astodrimmer
249 patients and 11.3% (33/291) for placebo.

250 Most AEs were mild or moderate in intensity, and self-limiting. During treatment, 1.7% (5)
251 women in each group reported severe AEs, but none were considered treatment related. In the
252 astodrimmer group, 1 participant discontinued treatment due to menorrhagia and 1 participant due
253 to vulvovaginal candidiasis, which was considered to be possibly related to treatment. In the
254 placebo group, 1 participant discontinued due to each of vulvovaginal candidiasis, type 2
255 diabetes mellitus, headache and abdominal pain, and 1 participant discontinued after
256 experiencing vaginal inflammation, vulvovaginal burning sensation, vulvovaginal pruritus and
257 BV considered possibly treatment related.

258 Serious AEs (other than pregnancy) were reported for 3/294 (1.0%) women in the astodrimmer
259 group and 3/291 (1.0%) in placebo, and none was considered to be potentially treatment related.

260 Vulvovaginal candidiasis was reported in 18.0% (53/294) and 13.7% (40/291) women in the
261 astodrimmer and placebo groups, respectively, during treatment and 20.1% [59/294] vs 17.2%
262 [50/291] for the overall study period. Vulvovaginal candidiasis considered potentially treatment-
263 related was reported in 6.8% (20/294) and 4.8% (14/291) of women using astodrimmer or placebo,
264 respectively, during treatment. During follow-up, vulvovaginal candidiasis rates were 4.1%

265 (12/294) for astodrimer and 5.8% (17/291) for placebo. During treatment, UTI rates were 7.8%
266 (23/294) for astodrimer and 2.4% (7/291) for placebo.

267 **Comment**

268 **Principal findings**

269 Astodrimer 1% Gel, administered every second day for 16 weeks, was effective and superior to
270 placebo for the prevention of BV recurrence in women with a history of recurrent BV. The
271 primary efficacy finding was supported by multiple secondary endpoints including significantly
272 longer time to recurrence and lower recurrence of symptoms, which was significant up to 8
273 weeks after end of treatment.

274 Astodrimer 1% Gel was well-tolerated, with the incidence of AEs generally similar between the
275 astodrimer and placebo arms. Rates of candidiasis were generally low.

276 **Results – efficacy**

277 The current study of Astodrimer 1% Gel represents the largest and first adequately powered,
278 randomized, placebo-controlled study of a therapy for preventing recurrent BV.

279 Some approved antibiotics or investigational therapies have been shown to reduce recurrence of
280 BV in limited clinical studies that have been generally non-randomized, not placebo-controlled,
281 and/or not adequately powered.^{7,21,22,23} Findings have not been replicated in larger randomized
282 controlled trials. Nevertheless, off-label regimens of products not approved for prevention,
283 including topical metronidazole, oral metronidazole and topical acid boric over periods of 4-6
284 months, together with fluconazole to prevent likely secondary candidiasis, are recommended for
285 long-term maintenance therapy for reducing recurrent BV,²⁴ even without confirmatory evidence.

286 The proportion of women with known BV recurrence (i.e., missing data not imputed) for
287 Astodrimmer 1% Gel (34.9% [88/252] vs 46.6% [116/249] for placebo) was comparable with that
288 seen in a similarly designed, but substantially smaller study of topically applied metronidazole
289 gel given for 16 weeks (25.5%).⁷

290 The difference in recurrence rates between astodrimmer and placebo narrowed progressively after
291 end of treatment, but women in the astodrimmer group recurred later than placebo, and therefore
292 had more recurrence free days. In addition, recurrence of symptoms of BV was statistically
293 significantly lower for astodrimmer compared with placebo up to Week 24, 8 weeks after end of
294 therapy, indicating a clinically meaningful residual benefit.

295 Treatment with astodrimmer helped maintain normal vaginal flora, with lower BV recurrence rates
296 as determined by Nugent score and the combination of Amsel criteria and Nugent score.

297 Overall, treatment with Astodrimmer 1% Gel for the prevention of BV recurrence was superior to
298 placebo across all efficacy endpoints: clinical (Amsel criteria), patient reported (symptoms) and
299 microbiological (Nugent score).

300 **Results – safety profile**

301 The proportion of women with vulvovaginal candidiasis receiving astodrimmer (18% during
302 treatment, 20.1% overall) was similar to placebo and less than half that reported during a study
303 of 16 weeks' treatment with topical metronidazole 0.75% gel (43.1% vs 20.5% in placebo).⁷

304 The slightly higher proportion of women with UTI for astodrimmer compared with placebo could
305 be potentially explained by the longer symptom-free period associated with use of astodrimmer
306 allowing a resumption of a more normal frequency of intercourse, consistent with slightly higher

307 sexual functioning scores observed in this study. In any case, the incidence of uncomplicated
308 UTI in young, sexually active women in the US is reported to be approximately 0.5 episodes per
309 person per year.²⁵ The incidence in women using astodrimmer in this study was 0.37 episodes per
310 person per year.

311 There were no other notable differences in AEs reported for astodrimmer and placebo.

312 **Clinical implications**

313 Astodrimmer is a novel dendrimer administered vaginally and is not systemically absorbed. Data
314 show that it inhibits formation of and disrupts biofilms due to its ability to block bacterial
315 adhesion. Given this profile, astodrimmer avoids issues typically associated with conventional
316 antibiotics, such as systemic side effects and antibiotic resistance, and is suitable as an effective
317 and safe alternative for the long-term management of recurrent BV, addressing an unmet medical
318 need.

319 Subgroup analyses showed statistically significant differences in clinical response between
320 astodrimmer and placebo in population groups with recognized risk factors for BV, such as black
321 women, those engaging in penile-vaginal sexual acts during the treatment period, and a high
322 screening NS of 7-10, suggesting clear benefit of the preventive treatment with astodrimmer in
323 these high-risk groups.

324 **Research implications**

325 The findings of this Phase 3 study support the clinical utility of Astodrimmer 1% Gel as a novel
326 treatment for prevention of BV recurrence in women suffering from recurrent BV. The product
327 has regulatory approval in Europe, Australia and a number of countries in Asia, and additional

328 safety information will be derived from routine post-market surveillance activities.

329 **Strengths and limitations**

330 The study is the largest randomized, double-blind, placebo-controlled study of a therapy to
331 prevent recurrent BV and was adequately powered to detect a difference in rates of BV
332 recurrence between astodrimin- and placebo-treated women.

333 The results of reduced recurrence of BV at Week 16 are consistent with the ability of Astodrimin
334 1% Gel to achieve clinical cure of BV at the end of a 7-day treatment period, as demonstrated in
335 phase 2 and 3 clinical studies.^{17,18}

336 The study was not stratified for race or other characteristics known to be associated with
337 recurrence of BV, although treatment groups were well balanced with respect to baseline
338 demographics. Subgroup analyses were exploratory in nature and results should be interpreted
339 with caution.

340 **Conclusions**

341 Astodrimin 1% Gel was effective at reducing recurrence of BV during 16 weeks' treatment and
342 was well-tolerated. This finding was robust and consistently supported across all types of
343 efficacy measure including patient-reported symptoms, clinical endpoints (Amsel criteria),
344 microbiological endpoints (Nugent score) and time to recurrence. Recurrence remained lower for
345 astodrimin compared to placebo up to 12 weeks after treatment had stopped.

346 The results from this large, adequately powered, well-controlled study support a role for
347 Astodrimin 1% Gel as an effective long-term therapy to prevent recurrence of BV with a novel,
348 non-antibiotic mechanism of action related to blocking of biofilms. The product acts locally and

349 is not systemically absorbed, and offers patients and clinicians a unique treatment option that
350 avoids potential issues associated with existing conventional antibiotics.

351 **Acknowledgments**

352 The authors would like to thank all the patients who were involved in the study and the Principal
353 Investigators for involvement with the clinical trial. Editorial and medical writing assistance was
354 provided by Angela Hart, MSc, of Quanticate UK Ltd, supported by Starpharma Pty Ltd, the
355 manufacturer of Astodrimmer Gel. The authors were fully responsible for the content, editorial
356 decisions, and opinions expressed in the current article. The authors did not receive an
357 honorarium related to the development of this manuscript.

358

359 **References**

- ¹ Barbone F, Austin H, Louv WC, Alexander WJ. A follow-up study of methods of contraception, sexual activity, and rates of trichomoniasis, candidiasis, and bacterial vaginosis. *Am J Obstet Gynecol* 1990;163(2):510-4.
- ² Bradshaw CS, Morton AN, Hocking J, et al. High recurrence rates of bacterial vaginosis over the course of 12 months after oral metronidazole therapy and factors associated with recurrence. *J Infect Dis* 2006;193:1478-86.
- ³ Hillier SL, Nugent RP, Eschenbach DA, et al. Association between bacterial vaginosis and preterm delivery of a low-birth-weight infant. The Vaginal Infections and Prematurity Study Group. *N Engl J Med* 1995;333:1737-42.
- ⁴ Schwebke JR. New concepts in the etiology of bacterial vaginosis. *Current Infectious Disease Reports* 2009;11(2):143-7.
- ⁵ Bilardi JE, Walker S, Temple-Smith M, et al. The burden of bacterial vaginosis: Women's experience of the physical, emotional, sexual and social impact of living with recurrent bacterial vaginosis. *PLoS ONE* 2013;8(9):e74378.
- ⁶ Peebles K, Velloza J, Balkus JE, McClelland RS, Barnabas RV. High global burden and costs of bacterial vaginosis: A systematic review and meta-analysis. *Sex Transm Dis* 2019;46(5):304-11.
- ⁷ Sobel JD, Ferris D, Schwebke J, et al. Suppressive antibacterial therapy with 0.75% metronidazole vaginal gel to prevent recurrent bacterial vaginosis. *Am J Obstet Gynecol* 2006. 194:1283-9.
- ⁸ Beigi RH, Austin MN, Meyn LA, Krohn MA, Hillier SL. Antimicrobial resistance associated with the treatment of bacterial vaginosis. *Am J Obstet Gynecol* 2004;191:1124-9.
- ⁹ Bradshaw CS, Vodstrcil LA, Hocking JS, et al. Recurrence of bacterial vaginosis is significantly associated with posttreatment sexual activities and hormonal contraceptive use. *Clin Infect Dis* 2013;56(6):777-86.

-
- ¹⁰ Bradshaw CS, Brotman RM. Making inroads into improving treatment of bacterial vaginosis – striving for long-term cure. *BMC Infect Dis* 2015;15:292-303.
- ¹¹ Bradshaw CS, Sobel JD. Current treatment of bacterial vaginosis - Limitations and need for innovation. *J Infect Dis* 2016;214(Suppl 1):S14-20.
- ¹² Swidsinski A, Mendling W, Loening-Baucke V, et al. Adherent biofilms in bacterial vaginosis. *Obstet Gynecol* 2005;106(5 Pt 1):1013-23.
- ¹³ Muzny CA, Schwebke JR. Biofilms: An underappreciated mechanism of treatment failure and recurrence in vaginal infections. *Clin Infect Dis* 2015;61(4):601-6.
- ¹⁴ Machado D, Castro J, Palmeira-de-Oliveira A, Martinez-de-Oliveira J, Cerca N. Bacterial vaginosis biofilms: Challenges to current therapies and emerging solutions. *Front Microbiol* 2016;6:1528.
- ¹⁵ McGowan I, Gomez K, Bruder K, et al. Phase 1 randomized trial of the vaginal safety and acceptability of SPL7013 Gel (VivaGel) in sexually active young women (MTN-004). *AIDS* 2011;25(8):1057-64.
- ¹⁶ O’Loughlin J, Millwood IY, McDonald HM, Price CF, Kaldor JM, Paull JRA. Safety, tolerability, and pharmacokinetics of SPL7013 Gel (VivaGel): A dose-ranging, phase I study. *Sex Transm Dis* 2010;37(2):100-4.
- ¹⁷ Waldbaum AS, Schwebke JR, Paull JRA, et al. A phase 2, double-blind, multicenter, randomized, placebo-controlled, dose-ranging study of the efficacy and safety of Astodimer Gel for the treatment of bacterial vaginosis. *PLoS ONE* 2020;15(5):e0232394.
- ¹⁸ Chavoustie SE, Carter BA, Waldbaum AS, et al. Two phase 3, double-blind, placebo-controlled studies of the efficacy and safety of Astodimer 1% Gel for the treatment of bacterial vaginosis. *Eur J Obstet Gynecol Reprod Biol* 2020;245:13-8.
- ¹⁹ Amsel R, Totten PA, Spiegel CA, Chen KCS, Eschenbach D, Holmes KK. Nonspecific vaginitis; Diagnostic criteria and microbial and epidemiologic associations. *Am J Med* 1983;74:14-22.
- ²⁰ Nugent RP, Krohn MA, Hillier SL. Reliability of diagnosing bacterial vaginosis is improved by a standardized method of gram stain interpretation. *J Clin Microbiol* 1991;29:297-301.

-
- ²¹ Reichman O, Akins R, Sobel JD. Boric acid addition to suppressive antimicrobial therapy for recurrent bacterial vaginosis. *Sex Transm Dis* 2009;36(11):732-4.
- ²² McClelland RS, Balkus JE, Lee J, et al. Randomized trial of periodic presumptive treatment with high-dose intravaginal metronidazole and miconazole to prevent vaginal infections in HIV-negative women. *J Infect Dis* 2015;211(12):1875-82.
- ²³ Cohen CR, Wierzbicki MR, French AL, et al. Randomized trial of lactin-V to prevent recurrence of bacterial vaginosis. *N Engl J Med* 2020;382:1906-15.
- ²⁴ Workowski KA, Bolan GA. Centers for Disease Control and Prevention (CDC). Sexually transmitted diseases treatment guidelines. *MMWR-Morbid Mortal W* 2015;64(RR-03):1-137.
- ²⁵ Medina M, Castillo-Pino E. An introduction to the epidemiology and burden of urinary tract infections. *Ther Adv Urol* 2019;11:3-7.

Tables

Table 1: Screening Characteristics (mITT population), by Treatment Group

	Astodrimmer Gel (N=294)	Placebo (N=291)
Age (yr)		
Mean [SD]	31.6 [7.23]	31.6 [6.99]
Range	18 to 45	18 to 45
Race, n (%)		
Black	147 (50.0)	141 (48.5)
White	115 (39.1)	113 (38.8)
All Others ^a	32 (10.9)	37 (12.7)
Ethnicity, n (%)		
Not Hispanic or Latino	209 (71.1)	206 (70.8)
Hispanic or Latino	85 (28.9)	85 (29.2)
Screening Nugent score, n (%)		
0 to 3	3 (1.0)	1 (0.3)
4 to 6	57 (19.4)	67 (23.0)
7 to 10	234 (79.6)	222 (76.3)
Missing	0	1 (0.3)
Number of BV episodes in 12 months prior to enrolment^b		
1	2 (0.7)	0
2	187 (63.6)	198 (68.0)
3 to 4	94 (32.0)	82 (28.2)
≥5	11 (3.7)	11 (3.8)

BV=bacterial vaginosis; SD=standard deviation

^a All Others = American Indian or Alaskan Native, Asian, Native Hawaiian or Other Pacific Islander, Other

^b Not including a current episode

Table 2: Efficacy Outcomes at or by Week 16 (mITT population), by Treatment Group

BV Recurrence Endpoint	Astodrimmer	Placebo	RR (95% CI ^b)	P value ^b
	n/N (%) [95% CI ^a]	n/N (%) [95% CI ^a]		
Primary Endpoint				
≥3 Amsel criteria	130/294 (44.2) [38.5, 50.1]	158/291 (54.3) [48.4, 60.1]	0.81 (0.69, 0.96)	0.015
Subject-reported BV Symptoms				
Vaginal Discharge	56/275 (20.4) [15.8, 25.6]	79/276 (28.6) [23.4, 34.3]	0.71 (0.53, 0.96)	0.025
Vaginal Odor	57/275 (20.7) [16.1, 26.0]	87/276 (31.5) [26.1, 37.4]	0.66 (0.49, 0.88)	0.004
Vaginal Discharge and/or Odor	75/269 (27.9) [22.6, 33.6]	108/266 (40.6) [34.6, 46.8]	0.69 (0.54, 0.87)	0.002
Individual Amsel Criteria				
Vaginal Discharge	97/276 (35.1) [29.5, 41.1]	125/276 (45.3) [39.3, 51.4]	0.78 (0.63, 0.95)	0.015
Positive Whiff Test	99/276 (35.9) [30.2, 41.8]	119/276 (43.1) [37.2, 49.2]	0.83 (0.68, 1.02)	0.082
Clue Cells ≥20%	104/274 (38.0) [32.2, 44.0]	132/273 (48.4) [42.3, 54.5]	0.79 (0.65, 0.95)	0.014
pH >4.5	175/276 (63.4) [57.4, 69.1]	175/276 (63.4) [57.4, 69.1]	1.00 (0.88, 1.14)	1.000
Composite Definition	81/276 (29.3) [24.0, 35.1]	111/276 (40.2) [34.4, 46.3]	0.73 (0.58, 0.92)	0.008
Nugent Score 7-10	95/240 (38.5) [32.4, 44.8]	135/273 (49.5) [43.4, 55.5]	0.78 (0.64, 0.95)	0.012

BV=bacterial vaginosis; CI=confidence interval; RR=relative risk

^a Clopper Pearson CI

^b Wald CI and P value

Table 3: Efficacy Outcomes During Follow-up (mITT population), by Treatment Group

Endpoint	Astodrimmer	Placebo	RR (95% CI ^b)	P value ^b
	n/N (%) [95% CI ^a]	n/N (%) [95% CI ^a]		
BV Recurrence (≥3 Amsel criteria)				
Week 20	191/294 (65.0) [59.2, 70.4]	203/291 (69.8) [64.1, 75.0]	0.93 (0.83, 1.04)	0.217
Week 24	194/294 (66.0) [60.3, 71.4]	213/291 (73.2) [67.7, 78.2]	0.90 (0.81, 1.00)	0.059
Week 28	197/294 (67.0) [61.3, 72.4]	206/291 (70.8) [65.2, 76.0]	0.95 (0.85, 1.06)	0.323
Subject-reported BV Symptoms – Vaginal Discharge and/or Odor				
Week 20	87/269 (32.3) [26.8, 38.3]	110/266 (41.4) [35.4, 47.5]	0.78 (0.62, 0.98)	0.031
Week 24	97/269 (36.1) [30.3, 42.1]	121/266 (45.5) [39.4, 51.7]	0.79 (0.64, 0.97)	0.027
Week 28	107/269 (39.8) [33.9, 45.9]	124/266 (46.6) [40.5, 52.8]	0.85 (0.70, 1.04)	0.111

BV=bacterial vaginosis; CI=confidence interval; RR=relative risk

^a Clopper Pearson CI

^b Wald CI and P value

Table 4: Tolerability (mITT population), by Treatment Group

Parameter	Astodrimer N=294 n (%)	Placebo N=291 n (%)
Patients with ≥ 1 AE	159 (54.1)	138 (47.4)
Patients with ≥ 1 AE considered by investigator to be potentially related to study treatment	37 (12.6)	33 (11.3)
Patients with ≥ 1 severe AE during treatment	5 (1.7)	5 (1.7)
Patients with ≥ 1 serious AE (other than pregnancy)	3 (1.0)	3 (1.0)
Patients who discontinued treatment due to AE (other than pregnancy)	2 (0.7)	5 (1.7)
Most frequent AEs during treatment (incidence $\geq 2\%$ for astodrimer)		
Vulvovaginal candidiasis	53 (18.0)	40 (13.7)
Urinary tract infection	23 (7.8)	7 (2.4)
Headache	15 (5.1)	18 (6.2)
Abdominal pain (upper, lower, not specified)	11 (3.7)	8 (2.7)
Vaginal discharge	9 (3.1)	4 (1.4)
Nasopharyngitis	8 (2.7)	13 (4.5)
Upper respiratory tract infection	8 (2.7)	6 (2.1)
Vulvovaginal pruritus	7 (2.4)	10 (3.4)

AE=adverse event

Figure Legends

Figure 1. CONSORT diagram

Figure 2. Kaplan-Meier survival curves for time to recurrence of bacterial vaginosis at or by Week 16 (modified intent-to-treat population)

^a Log-rank test for the difference between the survival curves of the two treatment groups

N=864
Patients Enrolled
(Open-label Oral Metronidazole)

N=586
Patients Randomized
(Double-blind Treatment Phase)

N=295
Astodrimer 1% Gel

N=291
Placebo Gel

N=294
Included in mITT

N=291
Included in mITT

N=1
Excluded from mITT
Not treated = 1

N=0
Excluded from mITT

